huHSC-(M-NSG)

品系全名

huHSC-(M-NSG)

目录号

NM-NSG-017

品系状态

活体

导出PDF

基因信息

基因名
IL2RG

基因曾用名

gc; p64; [g]c; CD132; gamma(c)

NCBI ID

16186

MGI ID

96551

Ensembl ID

ENSMUSG00000031304

Pubmed

IL2RG

人类同源基因

IL2RG

品系描述

人源化小鼠系将人的脐带血、胎肝造血干细胞（hHSC）移植到辐照清髓的M-NSG小鼠体内的模型。HSC移植后可以定植在小鼠骨髓，并不断产生各类造血或免疫细胞，如T细胞、B 细胞、NK 细胞、髓系细胞等。由于其免疫细胞是在小鼠体内发育而出，对小鼠宿主产生耐受，因而不会出现GvHD现象，人源免疫细胞将稳定存在，且重建后的免疫细胞类型较PBMC人源化小鼠丰富。
应用领域：肿瘤免疫研究；血液病研究；感染疾病研究； 基因治疗；无交叉反应的药物靶点研究；免疫原性试验

验证数据

表型分析

图片 3.png


图1. 人造血干细胞（HSCs）移植M-NSG小鼠重建造血系统，人源CD45+免疫细胞在小鼠外周血水平不断升高。

HSC-图2.png

图2. 人造血干细胞（HSCs）移植入小鼠体内20周时各类造血/免疫细胞的比例，包括人源T（CD3+CD4+和CD3+CD8+ cells）、B（CD19+ cells ）、NK淋巴细胞（CD56+CD16+ cells ）及单核细胞（CD14+CD11b+ cells）等。

图片 3_3.png

图3. 人造血干细胞（HSCs）移植M-NSG小鼠重建造血系统，并补充人源IL15，显著提升NK细胞比例，适合药物靶点在NK细胞上的药效评价。

image.png

图4. 人造血干细胞（HSCs）移植入小鼠体内各类造血/免疫细胞的比例。

image.png

图5. 不同Donor的人造血干细胞（HSCs）移植入小鼠体内各类造血/免疫细胞的比例。

药效评价

HSC-1.jpg

图6. Hu-HSC荷瘤小鼠模型抗肿瘤药效验证示例1

HSC-2.jpg

图7. Hu-HSC荷瘤小鼠模型抗肿瘤药效验证示例2

发表文献 8篇

1. MUC1 peptide-loaded dendritic cell vaccine boosts antitumor immunity in pancreatic cancer
发表年份：2026 来源杂志：Frontiers in Immunology

2. Tumor-Educated Extracellular Vesicle-Derived LINC01116 Drives Non-Small Cell Lung Cancer Progression and Immunosuppression by Sponging miR-3614-5p to Upregulate ARHGAP1
发表年份：2026 来源杂志：INTERNATIONAL IMMUNOPHARMACOLOGY

3. CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma
发表年份：2025 来源杂志：JOURNAL OF NANOBIOTECHNOLOGY

4. Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease
发表年份：2025 来源杂志：CELL

5. Targeting AURKA with multifunctional nanoparticles in CRPC therapy
发表年份：2024 来源杂志：JOURNAL OF NANOBIOTECHNOLOGY

6. Breaking Spatiotemporal Barriers of Immunogenic Chemotherapy via an Endoplasmic Reticulum Membrane-Assisted Liposomal Drug Delivery
发表年份：2023-05-19 来源杂志：ACS Nano

7. The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
发表年份：2023 来源杂志：Cellular & Molecular Immunology

8. Dual inhibition of innate immunity and apoptosis by human cytomegalovirus protein UL37x1 enables efficient virus replication
发表年份：2022 来源杂志：Nature Microbiology

展开

你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看

Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

查看

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

查看